FAMAR Group, a European pharmaceutical CDMO, has signed an agreement to acquire a sterile production site in Homburg, Germany, from MiP Pharma. The acquisition represents a strategic milestone in FAMAR’s growth journey, strengthening its footprint in high-value dosage forms and expanding its capabilities in aseptic and lyophilized fill & finish. The Homburg facility, which has recently undergone significant investment and modernization, will become an integral part of FAMAR’s internati...